Sarbani Chaudhuri, Chief Commercial and Medical Affairs Officer of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), filed a statement of changes in beneficial ownership on August 13, 2026, reporting a sale of common stock on August 11, 2026.

Key Highlights

  • Reporting person: Sarbani Chaudhuri, identified in the filing as Chief Commercial and Medical Affairs Officer of Rocket Pharmaceuticals, Inc.
  • Transaction: 4,701 shares of common stock disposed of (transaction code S) on August 11, 2026, at a price of $3.499 per share.
  • Purpose: According to the filing, the shares were sold to pay tax withholding obligations in connection with the vesting of RSUs.
  • Beneficial ownership following transaction: 262,809 shares of common stock held directly, including RSUs that convert to common stock on a one-for-one basis.
  • Filing date: August 13, 2026, signed by Martin Wilson as attorney-in-fact for Sarbani Chaudhuri.

Chaudhuri RSU Vesting Triggers Tax-Related Share Disposal at Rocket Pharmaceuticals

According to the filing, Sarbani Chaudhuri, who serves as Chief Commercial and Medical Affairs Officer at Rocket Pharmaceuticals, Inc., disposed of 4,701 shares of the company's common stock on August 11, 2026, at a price of $3.499 per share. The filing states that the sale was made specifically to satisfy tax withholding obligations arising from the vesting of restricted stock units, and was not characterized as a discretionary open-market sale for investment purposes.

The filing notes that Chaudhuri's reported holdings of 262,809 shares following the transaction include restricted stock units that convert to common stock on a one-for-one basis. Rocket Pharmaceuticals is a gene therapy company listed on NASDAQ under the symbol RCKT, focused on developing treatments for rare diseases. The filing was submitted on August 13, 2026, and was signed by Martin Wilson acting as attorney-in-fact for Chaudhuri. The transaction is reported as a direct ownership disposition under Table I of the filing, with no derivative securities transactions reported in Table II.

What Was Disclosed

The filing disclosed a sale of 4,701 common shares by Rocket Pharmaceuticals' Chief Commercial and Medical Affairs Officer on August 11, 2026, at $3.499 per share, conducted to cover tax withholding on vested RSUs, leaving the officer with 262,809 shares beneficially owned directly.